Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Roelf Valkema(Active Medicine (United Kingdom)), Eric P. Krenning(Cyclotron (Netherlands)), Stéphan Walrand, Larry K. Kvols(Moffitt Cancer Center), Janet Lasher, Stanislas Pauwels, Willem H. Bakker(Erasmus MC), Raffaella Barone, Dik J. Kwekkeboom(Erasmus MC), François Jamar(Cliniques Universitaires Saint-Luc), P.P.M. Kooij(Erasmus MC), Marion de Jong(Shell (Netherlands))
PubMed
January 1, 2005
Cited by 334
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814